So-called recapitalizations could accelerate in coming months as pharma commercialization platforms look for new partners with bigger tranches of capital.
More in demand, but scarcer after an M&A binge, market-access agencies have matured into one of the most coveted commercial niches. A new report from Houlihan Lokey explains why.